Kalapotharakos Grigorios, Högberg Thomas, Bergfeldt Kjell, Borgfeldt Christer
Department of Obstetrics & Gynecology, Skanes University Hospital, Lund, Sweden.
Department of Cancer Epidemiology, Skanes University Hospital, Lund, Sweden.
Acta Obstet Gynecol Scand. 2016 Apr;95(4):473-9. doi: 10.1111/aogs.12846. Epub 2016 Jan 20.
We conducted an evaluation of incidence and survival of women with borderline ovarian tumors in Sweden.
All women diagnosed with borderline ovarian tumor in the Swedish Cancer Register 1960-2007 (n = 6252) combined with follow up in the Swedish Death Registry to 1 July 2009 were included. Estimation of age-standardized relative survival rate according to time periods for diagnosis.
The incidence of borderline ovarian tumors increased during the study period, with a steep increase during the 1980s. The age standardized 5-year relative survival including all borderline tumors diagnosed 2000-07 was 97% (95% CI 92-99%). In women aged ≤64 years, the 10-year relative survival related to age at diagnosis of borderline tumors ranged from 95 to 98% and was 89% in women aged 65-74 years. In a multivariable analysis including age and decade of diagnosis relative survival for every decade increased. The 10-year relative survival in women with mucinous and serous borderline tumors did not differ significantly (p = 0.121).
Results of the present study are reassuring about long-term survival in women with borderline ovarian tumors. The age-standardized relative survival rate increased across time periods for diagnosis. There was no difference in long-term survival between mucinous and serous borderline ovarian tumors.
我们对瑞典交界性卵巢肿瘤女性的发病率和生存率进行了评估。
纳入所有在瑞典癌症登记处1960 - 2007年被诊断为交界性卵巢肿瘤的女性(n = 6252),并结合瑞典死亡登记处至2009年7月1日的随访数据。根据诊断时间段估计年龄标准化相对生存率。
在研究期间,交界性卵巢肿瘤的发病率有所上升,在20世纪80年代急剧上升。2000 - 2007年诊断的所有交界性肿瘤的年龄标准化5年相对生存率为97%(95%置信区间92 - 99%)。在年龄≤64岁的女性中,与交界性肿瘤诊断时年龄相关的10年相对生存率在95%至98%之间,65 - 74岁女性为89%。在包括年龄和诊断年代的多变量分析中,每十年的相对生存率都有所提高。黏液性和浆液性交界性肿瘤女性的10年相对生存率无显著差异(p = 0.121)。
本研究结果对于交界性卵巢肿瘤女性的长期生存令人安心。年龄标准化相对生存率随诊断时间段增加。黏液性和浆液性交界性卵巢肿瘤的长期生存率无差异。